Health
DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19 – News-Medical.Net
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3…
RedHill Biopharma Ltd. (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.
Opaganib is a novel, orally-administered sphingosine…
-
Business18 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News18 hours agoRent changes on way for hundreds of social housing recipients following government review
-
Business14 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News16 hours agoPolice reject claims about detained protester; SEQ train lines to be disrupted; BlueCare to cut enrolled nurses